(BIIB:Consolidated Issue Listed on NASDAQ Global Select )
Douglas Edward Williams Ph.D.
Executive Vice President of Research & Development, Biogen Inc.
|Age||Total Calculated Compensation||This person is connected to 71 board members in 6 different organizations across 15 different industries.|
See Board Relationships
As of Fiscal Year 2013
Dr. Douglas Edward Williams, also known as Doug, Ph.D. has been an Executive Vice President of Research & Development at Biogen Inc. since January 5, 2011. Dr. Williams served as Secretary of Fred Hutchinson Cancer Research Center. Dr. Williams served as the Chief Executive Officer of Zymogenetics Inc. from January 2, 2009 to November 2010. Dr. Williams served as the President of Zymogenetics Inc. from July 2, 2007 to January 2009. Dr. Williams joined ZymoGenetics Inc. ...
225 Binney StreetPhone: 617-679-2000
Cambridge, Massachusetts 02142
Board Members Memberships*
Former Chairman of The Board
Former Director and Director of Strategic Development and Health
Former Chief Technology Officer, Executive Vice President and Director
Former Director and Member of Compensation Committee
Former Independent Director, Chairman of Compensation Committee and Member of Corporate Governance & Nominating Committee
Former Director and Member of Audit Committee
Former Chief Executive Officer
Director and Member of Governance & Nominating Committee
State University of New York at Buffalo Roswell Park Memorial Institute Division
University of Massachusetts Lowell
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
|Giovanni Caforio M.D.||Chief Executive Officer and Director|
Bristol-Myers Squibb Company
|Omar S. Ishrak||Chairman and Chief Executive Officer|
|Robert J. Hugin MBA||Chairman, Chief Executive Officer and Chairman of Executive Committee|
|John C. Lechleiter Ph.D.||Chairman, Chief Executive Officer and President|
Eli Lilly and Company
|Lars Rebien Sørensen||Chief Executive Officer and Member of Executive Management|
Novo Nordisk A/S
|kr15.2M||Compensation as of Fiscal Year 2014.|